New drugs to improve transplant outcomes.
Fujisawa is committed to improving the outcomes of transplant patients worldwide. Research and development programs are underway for a new modified release dosage form of tacrolimus (MR-4), a new analog of leflunomide (FK 778), and several novel compounds (PG 490-88, AGI 1096) in collaboration with other companies. These programs are targeted to address many of the unmet medical needs in transplantation including (1) improving compliance, (2) reducing chronic rejection, and (3) improving long-term safety by reducing infectious and cardiovascular risk.
First
M Roy
MR
Fujisawa Healthcare, Inc., Deerfield, IL 60015, USA.
Fitzsimmons
William E
WE
D000480:Alkynes; D000818:Animals; D003692:Delayed-Action Preparations; D004224:Diterpenes / Q000627:therapeutic use; D004852:Epoxy Compounds; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007555:Isoxazoles / Q000627:therapeutic use; D009570:Nitriles; D010616:Phenanthrenes / Q000627:therapeutic use; D011341:Probucol / Q000031:analogs & derivatives / Q000627:therapeutic use; D016559:Tacrolimus / Q000627:therapeutic use
D000480:Alkynes; D003692:Delayed-Action Preparations; D004224:Diterpenes; D004852:Epoxy Compounds; D007166:Immunosuppressive Agents; D007555:Isoxazoles; D009570:Nitriles; D010616:Phenanthrenes; C115284:2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-hepten-6-ynamide; C001899:triptolide; D011341:Probucol; D016559:Tacrolimus